EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE 
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
As the SARS-CoV-2 (COVID-19) pandemic unfolded in 2020, Myeloma Patients Europe (MPE) became aware that the healthcare, treatment, and lives of myeloma and AL amyloidosis patients and their families were impacted by new health policies and national restrictions related to COVID-19.
In early 2020, we began to hear about a virus called SARS-CoV-2 (COVID- 19). No one could imagine that this virus would result in a global pandemic with huge changes in our daily life and, most important, in our healthcare.
Myeloma Patients Europe (MPE) held the webinar “COVID-19 vaccines for myeloma patients: what you need to know” last Thursday, 29 April, to review the most recent updates on the approved COVID-19 vaccines in Europe and how they affect myeloma and AL amyloidosis patients.
Myeloma Patients Europe (MPE) will hold a webinar to review the most recent updates on the approved COVID-19 vaccines in Europe and how they affect myeloma and AL amyloidosis patients.
As part of the CARAMBA consortium, Myeloma Patients Europe (MPE) has developed an information sheet to explain the main goals and characteristics of the CARAMBA clinical trial investigating SLAMF7 chimeric antigen receptor T-cell (CAR-T) therapy. This publication discusses some potential CAR-T side effects and considerations for patients and caregivers. This information sheet has been previously published on our website in English and is now available in four additional languages: French, Italian, Spanish and German.
Location: European Union or United Kingdom / home based Contract: Full-time (part time also possible)
Location: European Union or United Kingdom / home based Contract: Full-time (part time also possible)
Location: Scotland / home based (approx. 10 travel days per year) Contract: 40 hours per week / permanent Salary: £25,000 – £27,000 depending on experience This Research Assistant post supports the research function of Myeloma Patients Europe (MPE). There are two main elements to the job – supporting communication and dissemination of SISAQOL-IMI and to assist with generating patient centred evidence as part of MPE’s newly established Evidence Generation Unit (EGU). The following…
An international multidisciplinary consortium, guided by the European Organisation for Research and Treatment of Cancer (EORTC), has been convened to generate recommendations to standardize the use, analysis, and interpretation of PRO data in cancer clinical trials. Myeloma Patients Europe (MPE) is one of the partners in this project representing the Workgroup or European Cancer Patient Advocacy Networks (WECAN).
